

PATHOLOGY GRAND ROUNDS



Julien Sage, Ph.D.

Professor, Departments of Pediatrics and Genetics
Stanford University
Co-Director, Cancer Biology PhD Program

“Molecular and Cellular Mechanisms of SCLC Development and Response to Therapy”

Thursday, November 15th, 2018

12:30 p.m.

Fitkin Amphitheater – LMP 1094

Host: Narendra Wajapeyee, Ph.D.



There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

NEEDS ASSESSMENT

SCLC is a lethal neuroendocrine (NE) cancer that accounts for approximately 15% of all lung cancers and causes approximately 250,000 deaths worldwide each year. SCLC is linked to heavy cigarette smoking and exposure to carcinogens. Unfortunately, the number of SCLC-related deaths continues to rise. A major clinical challenge is that approximately 70% of SCLC patients have metastatic disease at time of diagnosis; these patients have a 5-year survival of <1%. Even patients

with localized disease at diagnosis have dismal survival rates. A second major challenge is that treatments for SCLC are inefficient and have remained mostly unchanged for the past 30 years with no new approved treatments since 1996 and no approved targeted therapies. SCLC is managed with first-line chemoradiation. Patients usually respond well initially but almost all relapse within months. There is a need to better understand the mechanisms underlying the aggressive growth and spread of SCLC and their rapid chemoresistance. At a gross level, SCLC tumors are quite “homogeneous” histologically (fields of similar-looking small blue round cancer cells) and genetically (ubiquitous loss Rb and p53). However, this simple view is at odds with the fact that approximately 40 phase 3 clinical trials have failed in the past approximately 40 years in SCLC patients. There is a need to define the heterogeneity of SCLC and leverage this understanding to

identify new therapeutic options

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Understand the key issues in the treatment of small cell lung cancer.
- Understand the Notch signaling pathway and its role in SCLC.
- Understand the diversity of cell types in the lung epithelium and in SCLC tumors.
- Understand that different cell types of origin may affect cancer development.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Speaker Name: Julien Sage, PhD - StemCentrx/Abbvie; Forty Seven, Inc.E

Course Directors: Manju Prasad, MD - NONE

Narendra Wajapeyee, PhD - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.